2,788 research outputs found
Rita B. Stadig Correspondence
No full textEntry is a handwritten biographical sketch of Rita Stadig author of Our Maine Heritage, a history of Maine
Case Management to Improve Uptake for Screening and Therapy of Hepatitis C viral infection in People Who Inject Drugs.
No full textIntroduction
Hepatitis C viral infection (HCV) has become a curable disease due to the development of direct acting antivirals (DAA). Therefore, the World Health Organization (WHO) has set a target to eliminate HCV. The largest group at risk for HCV at present are people who inject drugs (PWID), especially in the western world. Due to various barriers, this risk group is still underserved for HCV. Our goal was to study if a case management policy could improve uptake for screening and treatment for HCV in PWID.
Methods
We performed a prospective, interventional cohort study, evaluating the effect of case management on screening and treatment for HCV in PWID in an opiate substitution treatment (OST) setting in Limburg (Belgium). The goal was to address the PWID at this setting and to provide all the steps of the continuum of care, proposed by Meyer JP et al. (Int J Drug Policy, 2015). The cohort existed of four groups of PWID: firstly, a large group who received methadone at their local pharmacy. A second large group received methadone at the OST setting. Thirdly a smaller a group who were active users in a needle exchange program. And finally a small group who were recruited after referral to the hospital (former PWID).
Results
The results are presented in Figure 1. In all of the groups more than 80% of the cases were screened, except in the pharmacy group: these presented only a few times a year in the OST setting which could explain the lower screening rate. However, when addressed, more than 85% of the PWID in the pharmacy group were tested. In our PWID cohort, approximately 29% was HCV RNA positive. From these chronically infected PWID, 62% were assessed for treatment. 95% of them were eligible for antiviral treatment. However, treatment could only be started within the Belgian reimbursement criteria (requirement of F3 or F4 Metavir fibrosis score). As such, 51% were ruled out for therapy at present and treatment was started in 43%.
Conclusion
Case management is an effective way to screen a well-defined cohort of high-risk individuals for HCV and also improves treatment uptake
Keynote Speech by Rita Palacios and Luncheon
No full textRita Palacios holds a Ph.D. in Spanish and is a professor of languages in the School of Liberal Studies at Conestoga College in Kitchener, Ontario. Her research examines contemporary Maya literature from a cultural and gender studies perspective. She is the author of Unwriting Maya Literature: Ts’íib as Recorded Knowledge (with Paul M. Worley).
The luncheon is free for all registered participants
Case Management to Improve Uptake for Screening and Therapy of Hepatitis C viral infection in People Who Inject Drugs.
No full textIntroduction
Hepatitis C viral infection (HCV) has become a curable disease due to the development of direct acting antivirals (DAA). Therefore, the World Health Organization (WHO) has set a target to eliminate HCV. The largest group at risk for HCV at present are people who inject drugs (PWID), especially in the western world. Due to various barriers, this risk group is still underserved for HCV. Our goal was to study if a case management policy could improve uptake for screening and treatment for HCV in PWID.
Methods
We performed a prospective, interventional cohort study, evaluating the effect of case management on screening and treatment for HCV in PWID in an opiate substitution treatment (OST) setting in Limburg (Belgium). The goal was to address the PWID at this setting and to provide all the steps of the continuum of care, proposed by Meyer JP et al. (Int J Drug Policy, 2015). The cohort existed of four groups of PWID: firstly, a large group who received methadone at their local pharmacy. A second large group received methadone at the OST setting. Thirdly a smaller a group who were active users in a needle exchange program. And finally a small group who were recruited after referral to the hospital (former PWID).
Results
The results are presented in Figure 1. In all of the groups more than 80% of the cases were screened, except in the pharmacy group: these presented only a few times a year in the OST setting which could explain the lower screening rate. However, when addressed, more than 85% of the PWID in the pharmacy group were tested. In our PWID cohort, approximately 29% was HCV RNA positive. From these chronically infected PWID, 62% were assessed for treatment. 95% of them were eligible for antiviral treatment. However, treatment could only be started within the Belgian reimbursement criteria (requirement of F3 or F4 Metavir fibrosis score). As such, 51% were ruled out for therapy at present and treatment was started in 43%.
Conclusion
Case management is an effective way to screen a well-defined cohort of high-risk individuals for HCV and also improves treatment uptake
Validation of hepatitis C virus RNA detection using capillary blood by finger prick (GenXpert system)-Hepatitis C fingerprick study
No full textTo achieve the ambitious goals of the WHO to eliminate hepatitis C virus (HCV) infection as a public health threat by 2030, innovative approaches are needed to improve the uptake for screening and treatment in people who inject drugs (PWID). Important barriers to care are difficult venous access and the two-step approach in current point-of-care tests, using an HCV antibody screening test followed by a confirmatory HCV RNA test. In this study, we aimed to validate the new GenXpert instrument to diagnose HCV RNA by finger prick. This prospective study was conducted in a cohort of PWID in 6 alcohol/drug clinic sites and 1 outreach project in Belgium between January 2018 and March 2019. Plasma and capillary whole-blood samples were collected by venepuncture and finger prick, respectively. Sensitivity and specificity of the GenXpert system were compared to the gold standard Artus HCV RNA kit. Of 153 participants enrolled, 147 (96.1%) had results of both the GenXpert system and Artus HCV RNA kit available. HCV RNA was detected in 35 of 147 (23.8%) by the Artus HCV RNA kit and in 36 of 147 (24.8%) by the GenXpert. Median quantitative HCV RNA viral load on finger prick was 28 700 IU/mL (IQR 4070-65 875) vs 1 900 000IU/mL (IQR 416,466-2,265,510) on plasma. The GenXpert instrument had a sensitivity of 100% (95% CI 90%-100%) and a specificity of 99.1% (95.1%-99.9%). The overall diagnostic accuracy was 99.3% (96.3%-99.9%). This study validates the excellent performance of the GenXpert instrument to assess HCV RNA in capillary whole blood by finger prick in a PWID cohort.status: Publishe
Profile: Rita Davenport
No full textRita Davenport is an award-winning TV producer, host, author, inspirational humorist, world-renowned entrepreneur and public speaker. She\u27s the author of four bestselling books
Rita Dove, 8th Annual ODU Literary Festival
No full textDescribed as one of the most original and exciting young poets writing in America today, Rita Dove is the author of two volumes of poetry, The Yellow House on the Corner and Museum; her third full-length collection, Thomas and Beulah, is forthcoming from Carnegie-Mellon in 1986. In addition to her poetry, Dove has published fiction and essays in numerous magazines, journals and anthologies, including the highly acclaimed Morrow Anthology of Younger American Poets. Her poetry has won for her a Fulbright/Hays Fellowship, as well as fellowships from the National Endowment for the Arts and the Guggenheim Foundation. She is a member of the editorial board of National Forum and a contributing and advisory editor of Callaloo: A Black South Journal of Arts and Letters. Ms. Dove will read with Richard Shelton on Thursday afternoon
Rita Dove
No full textRita Dove visited The College at Brockport in March 1985 and May 1993. She is a poet and author, and was the first African-American to serve as Poet Laureate Consultant in Poetry to the Library of CongressArchived web contentSUNY BrockportWriters Forum Author Photo
Santa Rita del Cobre: a copper mining community in New Mexico
No full textIncludes bibliographical references and index.El Cobre: Spanish and Mexican mining in Apacheria -- Frontier mining: the underground years -- The Chino years: the open pit, the men, and their methods -- Santa Rita: the company town and the community -- The Kennecott era: modern technology and big labor -- Epilogue: mining and the environment -- Appendices -- List of churn and rotary drills at Santa Rita, 1908-1996 -- List of Chino shovels, 1910-2008 -- List of Chino locomotives, 1910-1970 -- Santa Rita workforce: numbers of employees, 1910-2001 -- Fatalities at Chino Mine properties, 1881-2005 -- Production and profits at Chino, 1801-2005 -- Daily wage rates at Chino, 1912-1996
Paul Bach-y-Rita, neuroscience's forgotten genius
No full textThesis: S.M. in Science Writing, Massachusetts Institute of Technology, Department of Humanities, Graduate Program in Science Writing, 2013.Cataloged from PDF version of thesis. Vita.Includes bibliographical references (pages 24-29).Dr. Paul Bach-y-Rita was a visionary neuroscientist and an early pioneer of the theory of neuroplasticity. He is the father of sensory substitution, a field which explores how one sensory modality can be transferred to another. This work culminated in the invention of the Brainport, a device that transmits information through electrodes on the tongue. Bach-y- Rita's company, Wicab, developed two versions of the Brainport. One uses visual information to reveal the sighted world to the blind; another uses body alignment information to help "wobblers" (individuals with vestibular conditions) navigate. The author received exclusive access to Bach-y-Rita's unpublished memoirs. These papers-supplemented by visits to Bach-y-Rita's home in Wisconsin and personal interviews with his family and colleagues-help tell the story of a revolutionary technology that failed to reach the public who needed it.by Aviva Hope Rutkin.S.M. in Science Writin
- …
